Patents Assigned to Wyeth
  • GASP1: a follistatin domain containing protein
    Patent number: 7585835
    Abstract: The present invention relates to the use of a protein, GASP1, comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of GASP1 for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Jennifer J. Hill, Neil M. Wolfman
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7585873
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler Adam Antane
  • Phenanthridine carbonyl phenols
    Patent number: 7585871
    Abstract: The present invention relates generally to phenanthridine carbonyl compositions such as substituted phenanthridine carbonyl phenols of Formula 1: wherein R1 to R15 are as defined in the specification, or pharmaceutically acceptable salts thereof; and methods of using them.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Robert John Steffan, William Jay Moore, Eugene J. Trybulski, Albert John Molinari
  • Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7585876
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: September 8, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
  • CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY
    Publication number: 20090220983
    Abstract: The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2.
    Type: Application
    Filed: February 26, 2009
    Publication date: September 3, 2009
    Applicant: Wyeth
    Inventors: Joanne Archambault, Stephen Berasi, Andrew Dorner, Scott Jelinsky
  • SYSTEMS AND METHODS FOR PROTEIN PRODUCTION
    Publication number: 20090221035
    Abstract: The invention relates to systems and methods for producing proteins of interest. The invention employs genetically-engineered animal or plant cells that have modified protein folding or processing capacities. In one aspect, the invention features genetically-engineered cells comprising one or more recombinant expression cassettes which encode (1) a protein of interest and (2) a polypeptide that is functional in the unfolded protein response (UPR) pathway of the cells. Co-expression of the polypeptide significantly increases the yield of the protein of interest in the genetically-engineered cells. In one example, the genetically-engineered cells are animal cells, and the co-expressed polypeptide is a component or modulator of an XB1- or ATF6-mediated UPR pathway.
    Type: Application
    Filed: April 6, 2009
    Publication date: September 3, 2009
    Applicant: WYETH
    Inventors: Yijie Gao, Nicole M. Piche, Mei Geng, Stephen H. Herrmann, Xiaotian Zhong, Ronald Kriz, Zhijian Lu
  • NUTRITIONAL FORMULATION
    Publication number: 20090220619
    Abstract: The present invention relates to nutritional supplements that provide an adult with essential vitamins and minerals that may be lacking in the adult's diet and prevent chronic diseases, such as osteoporosis. A number of combinations of nutrients in set ratios are provided to increase the body's ability to absorb and use the nutrients. These combinations are important in helping the body reach the proper balance required for maximized function. Because adults over the age of 50 years have different nutritional needs, nutritional supplements specifically designed for them are also provided.
    Type: Application
    Filed: April 3, 2007
    Publication date: September 3, 2009
    Applicant: Wyeth
    Inventors: Richard Cotter, Randy Stodard
  • TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
    Publication number: 20090221711
    Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
    Type: Application
    Filed: May 12, 2009
    Publication date: September 3, 2009
    Applicant: Wyeth
    Inventors: Alexander Michael Porte, Thomas Joseph Caggiano, George Diamantidis, Diane Barbara Hauze, Boyd Lynn Harrison, Molly Hoke, Anthony Kreft, Dennis M. Kubrak, Charles William Mann, Scott Mayer, Koi Michele Morris
  • Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
    Patent number: 7582636
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Joseph T. Lundquist, IV, Jeffrey C. Pelletier, Matthew D. Vera
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7582733
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 1, 2009
    Assignees: Elan Pharma International Limited, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha
  • Process for the synthesis of cPLA inhibitors
    Patent number: 7582771
    Abstract: A process for making the compound of formula (I) wherein Ac represents acetate; X represents O or CH2; Y represents C1-C6alkyl; and Z is selected from the group consisting of H, halogen, CN, CHO, CF3, OCF3, OH, C1-C6alkyl, C1-C6alkoxy, C1-C6thioalkyl, NH2, N(C1-C6alkyl)2, NH(C1-C6alkyl), NC(O)—(C1C6alkyl), and NO2. In his process, a compound of formula (II) is reacted with hydrazine to form a primary alkylamine, and then the primary alkylamine is reacted with acetic anhydride, to produce the compound of formula (I).
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Christoph M. Dehnhardt, Sreenivasulu Megati, Ronald S. Michalak, Panolil Raveendranath, Jianxin Ren, Charles C. Wu, Yangzhong Wu
  • 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
    Patent number: 7582634
    Abstract: The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Jeffrey C. Pelletier, John F. Rogers, Jr.
  • Dihydrospiro[dibenzo[a,d][7]annulene-5,4?-imidazol] compounds for the inhibition of beta-secretase
    Patent number: 7582667
    Abstract: The present invention provides a 10,11-dihydrospiro[dibenzo[a,d][7]annulene -5,4?-imidazol]-5?(1?H)-one compound of formula I Also provided are methods and compositions for the inhibition of ?-secretase (BACE) and the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Dominick Anthony Quagliato, Patrick Michael Andrae, Yi Fan
  • Substituted phenyl indoles
    Patent number: 7582773
    Abstract: The present invention relates generally to substituted phenyl indoles and methods of using them, for example as PAI-1 inhibitors.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventor: Eric Gould Gundersen
  • Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
    Patent number: 7582755
    Abstract: Methods for preparing cyclic carbamates and thiocarbamates containing cyanopyrrole moieties and of the formula are provided. Z are the same or different and are H, optionally substituted C1 to C6 alkyl, or CORA; RA is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl; Q are the same or different and are H, OH, NH2, CN, halogen, optionally substituted C1 to C6 alkyl, optionally substituted C2 to C6 alkenyl, optionally substituted C1 to C6 alkynyl, optionally substituted C1 to C6 alkoxy, optionally substituted C1 to C6 aminoalkyl, or CORB; and RB is H, optionally substituted C1 to C6 alkyl, optionally substituted C1 to C6 alkoxy, or optionally substituted C1 to C6 aminoalkyl.
    Type: Grant
    Filed: April 25, 2005
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventor: Bogdan Kazimierz Wilk
  • Structure of protein kinase C theta
    Patent number: 7584087
    Abstract: A three-dimensional structure of human protein kinase C theta (PKC?) can be used in methods of designing an agent that interacts with PKC?. The agent can be an inhibitor of PKC? activity.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Zhang Bao Xu, Stephane Olland, Scott Wolfrom, Karl Malakian, Laura Lin, Mark Stahl, Julie Lee, Lori Fitz, Rita Greco, Divya Chaudhary, William Stuart Somers, Lidia Mosyak
  • Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLAinhibitors
    Patent number: 7582772
    Abstract: The present invention provides method for making a compound of formula 1: comprising the steps of reacting compounds of formulas 2 and 3: to produce a compound of formula 4: wherein R1, R2, R3, R4 and R5 are defined as described herein. The compound of formula 4 is then converted to the compound of formula 1. The invention further comprises compounds of formulas 3 and 4 and methods for making compounds of formulas 3 and 4.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Ronald S. Michalak, Mahmut Levent, Frederick J. Vyverberg, Ara R. Boyajian, Panolil Raveendranath, Michel Cantin, Alan Stockton, Michael W. Winkley, Mousumi Ghosh, Christoph Dehnhardt, Charles Guinosso
  • SELECTIVE ACYLATION OF 4-SUBSTITUTED-1,3-PHENYLENEDIAMINE
    Publication number: 20090216046
    Abstract: This invention is directed to a method of selectively acylating a compound of formula (II): (II), wherein: R1 is NO2, —N+R33, trihalomethyl, —CN, —SO3H, —CO2H, —CO2 R3, —CHO and —COR3, wherein R3 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C12 cycloalkyl, C6-C12 aryl, C2-C9 heteroaryl, or C1-C9 heterocycloalkyl; comprising the step of reacting the compound of formula (II) with an acylating reagent to form a compound of formula (I): (I), wherein R2 is selected from C1-C12 alkyl, C1-C12 haloalkyl, C2-C7 alkenyl, C2-C7 alkynyl, C3-C12 cycloalkyl, C6-C12 aryl, C1-C9 heterocycloalkyl, C2-C9 heteroaryl, C1-C12 alkoxy, C1-C12 haloalkoxy, C3-C12 cycloalkoxy, C1-C9 heterocycloalkoxy, C6-C12 aryloxy, and C2-C9 heteroaryloxy; or salts thereof.
    Type: Application
    Filed: October 12, 2006
    Publication date: August 27, 2009
    Applicant: WYETH
    Inventor: Ronald Stanley Michalak
  • MAMMALIAN EXPRESSION SYSTEMS
    Publication number: 20090214513
    Abstract: The present invention features mammalian expression systems with improved production yields, and method of using these systems to produce desired proteins. In one embodiment, the expression systems of the present invention comprise genetically-engineered mammalian host cells cultured in a medium that contains an effective amount of heparin or heparin-like molecules. The presence of heparin or heparin-like molecules significantly increases protein production by the cultured cells. The present invention also features the use of constitutively-active components of FGFR-I-mediated signal transduction pathways to improve protein production by cultured mammalian cells. Co-expression of such a component with a protein of interest markedly increases the production yield of the protein of interest.
    Type: Application
    Filed: April 20, 2006
    Publication date: August 27, 2009
    Applicant: Wyeth
    Inventors: Xiaotian Zhong, Ronald William Kriz, Mark Lloyd Stahl
  • FXR agonists for treating vitamin D associated diseases
    Publication number: 20090215748
    Abstract: Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist.
    Type: Application
    Filed: December 19, 2008
    Publication date: August 27, 2009
    Applicant: Wyeth
    Inventor: Douglas Harnish